• Imatinib Hydrochloride: Precision Tyrosine Kinase Inhibition

  2026-05-20

  Imatinib hydrochloride (STI571 hydrochloride) enables highly reproducible, multi-target tyrosine kinase inhibition for dissecting oncogenic pathways in chronic myelogenous leukemia and gastrointestinal stromal tumor models. This guide synthesizes protocol refinements, workflow innovations, and troubleshooting insights inspired by recent dual-action kinase inhibitor discoveries.

• Sunitinib as a Multi-Targeted RTK Inhibitor: Applied Researc

  2026-05-19

  Sunitinib’s multi-targeted receptor tyrosine kinase inhibition unlocks new dimensions in tumor angiogenesis and apoptosis studies, particularly in renal cell carcinoma and nasopharyngeal carcinoma models. Recent research reveals how combination strategies, such as pairing sunitinib with chrysin, can overcome resistance and enhance outcomes, making it an indispensable asset for translational oncology workflows.

• Selective FGFR1 Inhibition by PD 173074 Dissects FGF-2 Neuro

  2026-05-19

  This study demonstrates that PD 173074 is a highly selective, nanomolar-potency inhibitor of FGFR1, capable of antagonizing FGF-2-dependent neurotrophic and neurotropic effects in central nervous system neurons. The findings establish PD 173074 as a precise molecular tool for dissecting FGF-2-mediated signaling in neuronal survival and differentiation, with minimal off-target impact on other neurotrophic pathways.

• Biotin-XX Tyramide Reagent: Enabling Ultra-Selective Cell Su

  2026-05-18

  Explore how Biotin-XX Tyramide Reagent transforms cell surface protein profiling with unprecedented selectivity and amplification. This article delves into advanced protocol design, mechanistic insights, and how this biotin-LC-LC-tyramide probe advances proximity labeling beyond current standards.

• Applied SB203580: Enhancing p38 MAPK Signaling Pathway Resea

  2026-05-18

  SB203580, a selective ATP-competitive p38 MAPK inhibitor, unlocks precise dissection of inflammatory and neuroprotective signaling in complex in vitro and in vivo models. This guide demystifies experimental workflows, protocol enhancements, and troubleshooting strategies to maximize reproducibility while leveraging insights from cutting-edge pain research.

• Sunitinib: Multi-Targeted RTK Inhibitor for Advanced Cancer

  2026-05-17

  Sunitinib enables multi-pathway inhibition in tumor models, making it the gold-standard scaffold for apoptosis and angiogenesis research. This article translates the latest experimental workflows and troubleshooting strategies, including synergy with Syringin, into actionable protocols for renal cell carcinoma and beyond.

• GSTA1 Drives Glutathione Depletion in α-Amanitin Hepatotoxic

  2026-05-16

  This study reveals that GSTA1, typically protective, paradoxically worsens α-amanitin-induced liver injury by accelerating glutathione depletion and oxidative stress. The findings identify GSTA1 as a direct therapeutic target and suggest that modulating glutathione metabolism could offer new intervention strategies for acute toxic liver damage.

• Dinaciclib (SCH727965): Precision CDK Inhibition in Cancer R

  2026-05-15

  Dinaciclib (SCH727965) brings nanomolar-range, multi-CDK inhibition to cutting-edge apoptosis and cell cycle research. Its robust performance in both in vitro and in vivo models, paired with actionable protocol insights, positions it as a cornerstone for dissecting cyclin-dependent kinase signaling and refining tissue boundary studies.

• Trichostatin A (TSA): Epigenetic Modulation and Immune Resil

  2026-05-15

  Discover how Trichostatin A (TSA) advances epigenetic regulation in cancer and immunity, with new insights into dendritic cell protection under hypoxia. This article reveals unique translational opportunities for TSA beyond established models.

• MOG (35-55) Peptide: Driving Advanced Autoimmune Encephalomy

  2026-05-14

  MOG (35-55) Peptide is the gold-standard inducer of experimental autoimmune encephalomyelitis, enabling precise modeling of neuroinflammation and therapeutic intervention in multiple sclerosis research. This guide translates recent advances in interferon signaling and practical workflow refinements into actionable strategies for optimizing assay fidelity and reproducibility.

• Pharmacokinetic Variability of Corydalis saxicola Alkaloids

  2026-05-14

  This study systematically characterizes how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics of Corydalis saxicola Bunting total alkaloids (CSBTA) in mice. It reveals that disease-driven modulation of metabolic enzymes and transporters, especially P-glycoprotein, significantly shifts drug distribution and exposure, informing rational clinical dosing strategies.

• LMO2-LDB1 Complex Drives AML Progression via Transcriptional

  2026-05-13

  This study elucidates how the interaction between LMO2 and co-regulator LDB1 promotes acute myeloid leukemia (AML) progression by supporting proliferation, survival, and colony formation of leukemic cells. The findings highlight the oncogenic role of the LMO2/LDB1 complex and its impact on gene regulation, providing a foundation for targeted therapeutic strategies in AML.

• Tacalcitol Monohydrate: Applied Workflows for NGF and Cancer

  2026-05-13

  Tacalcitol monohydrate, a synthetic analog of vitamin D3, uniquely empowers bench scientists to induce nerve growth factor (NGF) and enhance anticancer regimens with precision. This guide translates cutting-edge research into actionable protocols, troubleshooting, and workflow innovations for dermatology and oncology.

• MK-1775 Wee1 Kinase Inhibitor: Protocols, Use-Cases & Pitfal

  2026-05-12

  MK-1775, a potent and selective Wee1 kinase inhibitor, redefines experimental workflows for DNA damage response studies by enabling robust G2 checkpoint abrogation and chemosensitization in p53-deficient tumor models. This guide distills advanced use-cases, actionable parameters, and troubleshooting strategies, with direct translation from cutting-edge research.

• Afatinib (BIBW 2992): Optimizing EGFR Pathway Inhibition in

  2026-05-12

  Afatinib (BIBW 2992) stands out as an irreversible ErbB family inhibitor, enabling precise EGFR, HER2, and HER4 pathway interrogation in advanced cancer assembloid systems. This article dissects cutting-edge workflows and troubleshooting strategies for leveraging Afatinib in complex, patient-derived 3D models—empowering translational oncology and personalized therapy development.

15215 records 5/1015 page Previous Next 12345 下5页 Last page